Related Experiment Video

Updated: May 22, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Therapeutic regulation of complement in patients with renal disease - where is the promise?

Johua M Thurman1

  • 1Department of Medicine, University of Colorado Denver School of Medicine, Denver, CO, USA. Joshua.Thurman@UCdenver.edu

Clinical Nephrology
|May 4, 2012
PubMed

Insights

Complement inhibitors show promise for treating kidney diseases driven by complement activation. Eculizumab, a C5 inhibitor, offers potential new therapies, though optimal use requires further study.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Many kidney diseases involve harmful complement system activation in the kidneys.
  • Complement activation is a key factor in the development of these renal diseases.
  • Therapeutic complement inhibition has long been considered a potential treatment strategy.

Purpose of the Study:

  • To review the rationale for using complement inhibitors in renal diseases.
  • To discuss the current status and future directions of complement inhibitor therapies for kidney diseases.

Main Methods:

  • Review of existing literature on complement activation in renal diseases.
  • Analysis of clinical data and studies involving eculizumab in various renal conditions.
  • Discussion of emerging complement inhibitor drugs and therapeutic approaches.

Main Results:

  • Eculizumab, a C5 complement inhibitor, has demonstrated apparent efficacy in patients with several types of renal disease.
  • The use of eculizumab suggests a potential paradigm shift in treating complement-mediated kidney diseases.
  • Ongoing research is exploring various complement inhibitors and strategies.

Conclusions:

  • Complement inhibitors represent a promising therapeutic avenue for renal diseases.
  • Eculizumab's efficacy warrants further investigation into its optimal application in nephrology.
  • The development of novel complement-targeting drugs is advancing the treatment landscape for kidney diseases.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Concept Videos

Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...